Back to Journals » OncoTargets and Therapy » Volume 11

Role of the NFκB-signaling pathway in cancer

Authors Xia LZ, Tan SM, Zhou YJ, Lin JG, Wang HR, Oyang LD, Tian YT, Liu L, Su M, Wang H, Cao D, Liao QJ

Received 29 December 2017

Accepted for publication 9 February 2018

Published 11 April 2018 Volume 2018:11 Pages 2063—2073

DOI https://doi.org/10.2147/OTT.S161109

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly


Longzheng Xia,1,* Shiming Tan,1,* Yujuan Zhou,1 Jingguan Lin,1 Heran Wang,1 Linda Oyang,1 Yutong Tian,1 Lu Liu,1 Min Su,1 Hui Wang,1 Deliang Cao,1,2 Qianjin Liao1

1Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, China; 2Department of Medical Microbiology, Immunology, and Cell Biology, Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL, USA

*These authors contributed equally to this work

Abstract: Cancer is a group of cells that malignantly grow and proliferate uncontrollably. At present, treatment modes for cancer mainly comprise surgery, chemotherapy, radiotherapy, molecularly targeted therapy, gene therapy, and immunotherapy. However, the curative effects of these treatments have been limited thus far by specific characteristics of tumors. Abnormal activation of signaling pathways is involved in tumor pathogenesis and plays critical roles in growth, progression, and relapse of cancers. Targeted therapies against effectors in oncogenic signaling have improved the outcomes of cancer patients. NFκB is an important signaling pathway involved in pathogenesis and treatment of cancers. Excessive activation of the NFκB-signaling pathway has been documented in various tumor tissues, and studies on this signaling pathway for targeted cancer therapy have become a hot topic. In this review, we update current understanding of the NFκB-signaling pathway in cancer.

Keywords: nuclear factor kappa-B, p65, signaling pathway, cancer, inflammation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]